CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean C. Tien, Arul M. Chinnaiyan, Ke Ding et al.|Cell Reports Medicine|2024Cited by 28
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean C. Tien, Arul M. Chinnaiyan, Ke Ding et al.|Proceedings of the National Academy of Sciences|2025Cited by 6
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean C. Tien, Arul M. Chinnaiyan, James Neiswender et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 1
Abstract PR010: <i>CDK12</i> loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethalityJean C. Tien, Arul M. Chinnaiyan, Ke Ding et al.|Molecular Cancer Therapeutics|2024Cited by 0